Multiple-drug therapy for tuberculosis (TB)

References

Citations

1. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2003). Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4): 603–662.

2. Centers for Disease Control and Prevention (2001). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations. MMWR, 50(34): 733–735.

3. Small PM, Selcer UM (2000). Tuberculosis. In GT Strickland, ed., Hunter's Tropical Medicine and Emerging Infectious Diseases, 8th ed., pp. 491–513. Philadelphia: W.B. Saunders.

4. Centers for Disease Control and Prevention (1998). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR, 47(RR-20): 1–51. Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm.

5. Schluger NW (1999). Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases, 28(1): 130–135.

Author:	Maria G. Essig, MS, ELS	Last Updated: May 16, 2007
Medical Review:	E. Gregory Thompson, MD - Internal Medicine Alfred A. Lardizabal, MD - Pulmonology and Critical Care Medicine/Tuberculosis
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.